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ThromboelastometryFibrinogen, a soluble 340 kDa plasma glycoprotein, is critical in achieving and maintaining hemostasis. Reduced
ﬁbrinogen levels are associated with an increased risk of bleeding and recent research has investigated the
efﬁcacy of ﬁbrinogen concentrate for controlling perioperative bleeding. European guidelines on the manage-
ment of perioperative bleeding recommend the use of ﬁbrinogen concentrate if signiﬁcant bleeding is accompa-
nied by plasma ﬁbrinogen levels less than 1.5–2.0 g/l. Plasma-derived human ﬁbrinogen concentrate has been
available for therapeutic use since 1956. The overall aim of the comprehensive series of non-clinical investiga-
tions presented was to evaluate i) the pharmacodynamic and pharmacokinetic characteristics and ii) the safety
and tolerability proﬁle of human ﬁbrinogen concentrate Haemocomplettan P® (RiaSTAP®). Pharmacodynamic
characteristics were assessed in rabbits, pharmacokinetic parameters were determined in rabbits and rats and a
safety pharmacology study was performed in beagle dogs. Additional toxicology tests included: single-dose
toxicity tests in mice and rats; local tolerance tests in rabbits; and neoantigenicity tests in rabbits and guinea pigs
following the introduction of pasteurization in the manufacturing process. Human ﬁbrinogen concentrate was
shown to be pharmacodynamically active in rabbits and dogs andwell tolerated, with no adverse events and no in-
ﬂuence on circulation, respiration or hematological parameters in rabbits, mice, rats and dogs. In these non-clinical
investigations, humanﬁbrinogen concentrate showed a good safety proﬁle. This data adds to the safety information
available to date, strengthening the current body of knowledge regarding this hemostatic agent.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Fibrinogen is a soluble plasma glycoprotein with amolecular weight
of 340 kDa. It is synthesized and secreted by the liver, and is critical in
achieving and maintaining hemostasis. The structure of ﬁbrinogen is
complex; each molecule consists of two identical subunits composed
of three pairs of non-identical polypeptide chains (α2, β2, γ2). During
coagulation ﬁbrinogen is cleaved by thrombin, which results in the re-
lease of ﬁbrinopeptide A and ﬁbrinopeptide B; its subsequent polymer-
ization to form ﬁbrin strands provides the structural network required
for clotting. Fibrin ﬁbers are covalently cross-linked by activated coagu-
lation factor XIII (Muszbek et al., 1999). In addition, ﬁbrinogen pro-
motes platelet aggregation by binding platelet glycoprotein IIb/IIIa
receptors; these platelets become enmeshed within the ﬁbrin strands,
strengthening the clot. Its contribution to both primary and secondarycology/Toxicology, Preclinical
on-Behring-Strasse 76, 35041
yerle).
. This is an open access article underhemostasis led it to be described as a “potential universal hemostatic
agent” (Fenger-Eriksen et al., 2009a).
Congenital ﬁbrinogen deﬁciency, a rare bleeding disorder, affects
either the quantity (aﬁbrinogenemia and hypoﬁbrinogenemia) or qual-
ity (dysﬁbrinogenemia) of circulating ﬁbrinogen. Fibrinogen levels are
associated with clinical bleeding severity (Peyvandi et al., 2012). Re-
placement therapy with human ﬁbrinogen concentrate has been
shown to be effective and generally well tolerated in treating bleeding
episodes in congenital ﬁbrinogen deﬁciency (Kreuz et al., 2005a).
Guidelines recommend that the dose and frequency of administration
should be adjusted to maintain a plasma ﬁbrinogen level N0.5–1.0 g/l
(Bolton-Maggs et al., 2004).
In a healthy individual, normal plasma levels of ﬁbrinogen range
from 2.0 to 4.5 g/l (Fenger-Eriksen et al., 2009a). Reduced ﬁbrinogen
levels appear to be correlated with an increased risk of bleeding in dif-
ferent clinical settings (Blome et al., 2005; Charbit et al., 2007;
Karlsson et al., 2008). Recent studies have shown that humanﬁbrinogen
concentrate is efﬁcacious in controlling perioperative bleeding, restor-
ing clotting and reducing both post-operative blood loss and require-
ment for allogeneic blood products (Görlinger et al., 2011; Karlsson
et al., 2009; Rahe-Meyer et al., 2013a,b; Solomon et al., 2010).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Characteristics of the animals used anddoses of humanﬁbrinogen concentrate administered
in each of the studies.








2 Rabbit/CHB/f 50 — IV 2.5–3.0 kg
3 Rat/CD/f 60 — IV N180 g
Safety pharmacology
4 Dog/Beagle/f and m 20/100/200 — IV 8.5–13.5 kg
Single-dose toxicity
5 Mouse/NMRI/f and m 250/500/1000 — IV 19.1–23.2 g
6 Rat/Wistar/f and m 100/200/300 — IV 110.3–137.6 g
Local tolerance
7, 8, 9 Rabbit/NZW/f 40 — IV/40 — IA/0.8 — PV 220–268 g
Neoantigenicity




13 Rabbit/NZW/f and m 100 — IV 2–3 kg
f, female; IA, intra-arterial; IV, intravenous; m, male; PV, paravenous.
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levels (Lang et al., 2009; Velik-Salchner et al., 2007). Consistent with
these ﬁndings, European guidelines on the management of severe
bleeding in the perioperative (Kozek-Langenecker et al., 2013) and
trauma (Spahn et al., 2013) settings recommend the use of ﬁbrinogen
concentrate if signiﬁcant bleeding is accompanied by plasma ﬁbrinogen
concentrations less than 1.5–2.0 g/l.
A plasma-derivedhumanﬁbrinogen concentrate (CSL BehringGmbH,
Marburg, Germany) was ﬁrst approved for use in Brazil in 1963. In 1985,
pasteurization was introduced in the manufacturing process, and the
pasteurized product has been available since 1986 (Fenger-Eriksen
et al., 2009a). Throughout the product's licensing history it has been
known under the following trade names: Haemocomplettan® HS (heat
sterilized) or P (pasteurized; Europe), and RiaSTAP® (USA). Currently,
under the trade name Haemocomplettan® P, the product is approved
for the treatment and prophylaxis of hemorrhagic diatheses in congenital
and acquiredﬁbrinogendeﬁciency (Haemocomplettan®PI, 2008) in sev-
eral countries all over the world (Solomon and Wendt, 2014). The same
product, licensed under the trade name RiaSTAP®, is also available in a
number of countries world-wide (Solomon and Wendt, 2014) for the
treatment of acute bleeding episodes in patients with congenital ﬁbrino-
gen deﬁciency, including aﬁbrinogenemia and hypoﬁbrinogenemia
(Riastap® PI, 2011). Further details of the current licensing information
for human ﬁbrinogen concentrate are described in a recent review by
Levy et al. (2014).
The product is subjected to pasteurization (heat treatment at 60 °C
for 20 h in aqueous solution), to reduce the risk of viral transmission,
(Gröner, 2007) and precipitation and puriﬁcation. Recent data from
prospective controlled studies support the safety of human ﬁbrinogen
concentrate across a variety of clinical settings, including cardiovascular
surgery, trauma and burn patients (Görlinger et al., 2012; Rahe-Meyer
et al., 2013a,b; Schaden et al., 2012; Weber et al., 2012). Additional ev-
idence from retrospective studies (Schöchl et al., 2010, 2011) and case
series (Bell et al., 2010) have also been reported.
The overall aim of the comprehensive series of investigations in
healthy non-bleeding animals presented here was to evaluate: i) the
pharmacodynamic and pharmacokinetic characteristics; and ii) the
safety and tolerability proﬁle of human ﬁbrinogen concentrate. With
the growing interest and increased clinical use of human ﬁbrinogen
concentrate, the data provided by the studies presented here will be
valuable and further extends the current body of knowledge on this he-
mostatic agent.
Materials and methods
The studieswere approved by the local governmental ethics commit-
tee. Testing was performed according to relevant European guidelines
applicable to the non-clinical safety assessment of human plasma-
derived products. Animal care and treatment were in compliance with
all pertinent regulations of the European Union and Germany. The
characteristics of the animals used in each study and the doses of
human ﬁbrinogen concentrate administered (Haemocomplettan®
P, CSL Behring GmbH, Marburg, Germany) are described in Table 1.
The animal species used for these studies (e.g., dogs, mice, rabbits,
and rats) were chosen because human ﬁbrinogen is pharmacologically
active in these species (Karges et al., 1994; Siller-Matula et al., 2008).
Coagulation factors are highly conserved and there is evidence that
human coagulation factors work in the animal coagulation system
(e.g., in hemophilia A or B). The human ﬁbrinogen used in these studies
is cleaved by its target animal serine protease, thrombin. It has already
been shown that impaired thromboelastography in rats can be normal-
ized by the administration of human ﬁbrinogen (Kaspereit et al., 2004).
In accordance with regulatory requirements, both genders were inves-
tigated in the safety pharmacology study in beagle dogs and in the
single-dose toxicity studies inmice and rats. The doses of human ﬁbrin-
ogen concentrate used in the pharmacodynamic and pharmacokineticstudies correspond to a standard human dose of 4–5 g for an 80 kg per-
son. For the safety pharmacology study and all toxicity studies a number
of multiple doses of the standard human dose were used to investigate
worse case scenarios for accurately evaluating the toxicity of human ﬁ-
brinogen concentrate.Pharmacodynamic and pharmacokinetic studies
One study, using thromboelastometry (ROTEM), analyzed the phar-
macodynamic efﬁcacy of human ﬁbrinogen concentrate (Study 1). Rab-
bits (n = 8; all females) were restrained; a 14 G catheter was
introduced into the carotid artery for blood sampling and a 20 G cathe-
ter was introduced into the jugular vein for blood withdrawal. Rabbits
were injected successively with 50 mg/kg (2.5 ml/kg body weight
over 1 min) human ﬁbrinogen concentrate at ﬁve minute intervals,
resulting in a cumulative dose of 250 mg/kg. One milliliter blood sam-
ples (10% v/v sodium citrate) were withdrawn at baseline (time = 0)
and 1 min after each infusion; the effects of human ﬁbrinogen concen-
trate on ROTEM parameters were monitored. FIBTEM was performed
in whole blood using a ROTEM® analyzer (Tem International, Munich,
Germany); the test reactionwas initiated through the extrinsic pathway
and cytochalasin D was added to inhibit platelet activity. The primary
variable for assessing the quality of the ﬁbrin-based clot wasmaximum
clot ﬁrmness (MCF) using the FIBTEM test.
Two studies analyzed the pharmacokinetic properties of human
ﬁbrinogen concentrate. In the ﬁrst of these studies (Study 2), rabbits
(n= 10; all females) received 50 mg/kg human ﬁbrinogen concentrate
as a single bolus intravenous injection. Blood samples were obtained at
the following time points: before injection and 5 min, 30 min, and 1, 2,
4, 6, 8, 24, 32, 48, 72 and 96 h after administration. In the second of
these studies (Study 3), rats (n = 6; all females) received a single
bolus intravenous injection of 60 mg/kg human ﬁbrinogen concentrate.
Blood samples were obtained at the following time points: 5 min,
30 min, 60 min, and 2, 4, 8, 24 and 32 h after administration. In both
studies, blood samples were collected into 20% sodium citrate (3.13%
w/v) and plasma was separated immediately. Each plasma sample
was used to quantify human ﬁbrinogen antigen concentration using a
validated ELISA technique according to the manufacturer's instructions
(Study 2: AssayPro LLC, St. Charles,MO; Study 3: Cedarlane Laboratories
Ltd., Burlington, NC). The following pharmacokinetic variables of
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recovery, area under the curve (AUC), clearance and terminal half-life
(t1/2).
Safety pharmacology
Before the start of the treatment procedure, dogs (n = 6; 3 females
and 3males) were narcotizedwith Nembutal (0.5 ml/kg intravenously)
and catheters for injection were placed into the jugular vein, catheters
for blood collection were placed into the carotid artery and devices for
recording physiological body functions were placed into the trachea
(Study 4). Three successive doses of human ﬁbrinogen concentrate
(20, 100 and 200 mg/kg) were injected at 5 minute intervals, at a rate
of 5 ml/min, into the jugular vein. Animals were observed at the follow-
ing time points: before injection; after each injection; and 15 min,
30 min and 60 min after the ﬁnal injection. During the observation
period the following circulatory and respiratory parameters were
examined: arterial blood pressure; heart and pulse rates; cardiac output
per minute; peripheral resistance; heart efﬁciency; central body tem-
perature; electrical activity of the heart; ventricular contractility;
pneumatogram; respiratory rate; and blood pressure. Blood samples
were drawn from the carotid artery for hematological investigation, in-
cluding hemoglobin, hematocrit, leukocytes, erythrocytes and platelet
counts. In addition, blood coagulation and clinical chemistry analysis
parameters were determined. Investigationswere performed according
to manufacturer's instructions: thrombelastography (TEG) parameters
were measured using the Hellige device (Hellige GmbH, Freiburg,
Germany); prothrombin time (Quick test) was determined with
Thromborel® S (Siemens Healthcare Diagnostics, Marburg, Germany);
partial thromboplastin time was measured with Pathrombin® SL
(Dade Behring, Liederbach, Germany); and thrombin timewas assessed
with Thrombin 30 IU/ml (Haematologic Technologies, Inc., Essex
Junction, VT). Plasma ﬁbrinogen levels were measured by the Clauss
method in a steel ball coagulometer KC10 (Amelung GmbH, Lemgo,
Germany) usingMultiﬁbren (Siemens Healthcare Diagnostics,Marburg,
Germany).Whole blood clotting time (WBCT)was carried out using the
Lee and White water bath method (Lee and White, 1913).
Single-dose toxicity
Two studies analyzed the acute toxicity of human ﬁbrinogen con-
centrate. In the ﬁrst of these studies (Study 5), mice (n = 10 in each
of 4 groups; 5 females and 5males) received either a single intravenous
injection of isotonic saline or 250, 500 or 1000 mg/kg human ﬁbrinogen
concentrate, respectively, into the tail vein at a rate of 1 ml/min. In
the second of these studies (Study 6), rats (n = 10 in each of 4 groups;
5 females and 5 males) received either a single intravenous injection of
isotonic saline or 100, 200 or 300 mg/kg human ﬁbrinogen concentrate,
respectively, into the tail vein at a rate of 5 ml/min. In both studies, all
animals were randomly assigned to their respective treatment groups
using an in-house computer program, given a unique identiﬁcation
number and identiﬁed by color marks. The animals were observed im-
mediately following treatment and daily thereafter for 14 days and
were weighed on study days 1, 2, 8 and 15. Dissection and macroscopic
examination were performed at the end of the observation period on
study day 15.
Local tolerance
The local tolerability of human ﬁbrinogen concentrate was analyzed
in three studies. In each study, rabbits (n = 5; all females) received
human ﬁbrinogen concentrate as an intravenous (40 mg/kg; Study 7),
intra-arterial (40 mg/kg; Study 8) or paravenous (0.8 mg/kg; Study 9)
injection into the right ear and isotonic NaCl (control substance) into
the left ear. Clinical observations (e.g., reddening at injection sites,
fever or abnormal behavior) were performed at the following timepoints: day 1 (immediately after injection), day 2 and day 3 after intra-
venous or intra-arterial injection and days 2, 3 and 8 after paravenous
injection. The animals were euthanized on day 3 after intravenous or
intra-arterial injection and day 8 after paravenous injection. The injec-
tion sites were removed, ﬁxed in formalin-alcohol and embedded in
plastic (methylmethacrylate). The resulting slides were stained with
hematoxylin and eosin and investigated histologically.Neoantigenicity studies
Three studies analyzed the potential of neoepitope formation based
on the introduction of heat treatmentwithin themanufacturing process
of human ﬁbrinogen concentrate. In the ﬁrst of these studies (Study 10),
rabbits (n = 5 for each group; all males) received 3 weekly repeated
subcutaneous injections (days 1, 7 and 14) of either unheated or heated
human ﬁbrinogen concentrate (8 mg/kg) in the presence of Freund's
complete adjuvant. In the second of these studies (Study 11), rabbits
(n = 5 for each group; all males) received 3 weekly repeated subcuta-
neous injections (days 1, 8 and 15) of either unheated (Groups 1 and
3) or heated (Group 2: 20 h/60 °C; Group 4: 10 h/60 °C) human ﬁbrin-
ogen concentrate (4 mg/kg) in the presence of Freund's complete adju-
vant. In the third of these studies (Study 12), rabbits (n = 5 for each
group; all males) received 3 weekly repeated subcutaneous injections
(days 1, 8 and 15) of either unheated or heated (20 h/60 °C) human ﬁ-
brinogen concentrate (4 mg/kg) in the presence of Freund's complete
adjuvant. On day 22 (Studies 11 and 12) or day 23 (Study 10) following
immunization, blood samples were collected from each animal by
cardiocentesis and precipitating antibodies against the immunizing
agent were measured by either the Ouchterlony test or the passive cu-
taneous anaphylaxis test performed in guinea pigs (female and male).
Detailed methodology has been published previously (Ronneberger,
1986).
In a further study of neoantigenicity (Study 13), rabbits (n = 6; 3
females and 3males) were immunized intravenously with either un-
heated or heated human ﬁbrinogen concentrate (100 mg/kg) in the
absence of Freund's complete adjuvant. After 30–40 days from the
start of immunization, a blood sample was taken and the serum
was applied to a Protein A column (Pierce, Rockford, IL) to obtain
the IgG fraction. Native Western blot was performed using a Bio-
Rad Criterion cell (Bio-Rad, Hercules, CA) according to the
manufacturer's instructions.Statistical analysis
Pharmacokinetic studies. Pharmacokinetic variables were estimated
by non-compartmental methods.Results
Pharmacodynamic and pharmacokinetic studies
Following intravenous administration of human ﬁbrinogen concen-
trate to rabbits, there was a dose-dependent increase in A5, A10
and MCF parameters of the FIBTEM test after cumulative dosing of
250 mg/kg (Table 2 and Figs. 1A/B).
The elimination curves and pharmacokinetic parameters of human
ﬁbrinogen concentrate in rabbits and rats are shown in Fig. 2. The
AUC, t1/2 and clearance of human ﬁbrinogen concentrate in rabbits
and rats appear to be comparable. The in vivo recovery was deﬁned as
the highest plasma concentration observed (Cmax) in relation to
the dose applied divided by the plasma volume of approximately
40 ml/kg for rabbits and rats. Of note, in vivo recovery was slightly
higher in rabbits than in rats (79% vs. 65%).
Table 2
FIBTEManalysis ofwhole blood following intravenous administration of humanﬁbrinogen
concentrate to rabbits (Study 1).
Human ﬁbrinogen concentrate (mg/kg) A5 A10 MCF
Mean SEM Mean SEM Mean SEM
Baseline 13.9 0.7 14.5 0.8 14.4 0.8
50 22.5 0.8 22.8 0.9 22.9 0.8
100 28.2 0.9 28.8 0.9 28.9 0.9
150 34.5 1.0 34.9 1.1 35.1 1.2
200 39.7 0.9 40.4 1.1 40.6 1.1
250 45.5 1.0 45.8 1.0 46.4 1.1
A5, clot amplitude at 5 min; A10, clot amplitude at 10 min; MCF, maximum clot ﬁrmness;
SEM, standard error of the mean.
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After successive dosing of human ﬁbrinogen concentrate, a dose-
dependent increase in ﬁbrinogen levels was detected (Fig. 3A) that
was sustained after the last injection over the remaining time of the ob-
servation period of 60 min. A moderate increase in thrombin time was
observed after the ﬁrst injection of human ﬁbrinogen concentrate
(Fig. 3B) and a moderate increase in whole blood clotting time was ob-
served after the second injection of human ﬁbrinogen concentrate
(Fig. 3C). Over the 60 minute observation period, no change in partial
thromboplastin time (Fig. 3D) ormaximumamplitude (Fig. 3E) was de-
tected following successive dosing of human ﬁbrinogen concentrate.
Comparedwith baseline levels, glucose levels were slightly increased
after theﬁnal injection of human ﬁbrinogen concentrate (females: 6.3±
1.3 mmol/l vs. 7.3 ± 0.7 mmol/l; males: 6.1 mmol/l ± 0.8 vs. 8.1 ±
0.6 mmol/l) and remained increased until the end of the 60 minute ob-
servation period (females: 8.1± 1.1 mmol/l; males: 9.1± 0.67 mmol/l)
(Fig. 4A). Compared with baseline levels, urea levels were slightly in-
creased 15 min after the last injection (females: 3.3 ± 1.1 mmol/l vs.
3.3–4.5 mmol/l; males: 2.8 ± 0.96 mmol/l vs. 2.8–4.2 mmol/l) and
remained increased until the end of the observation period (Fig. 4B).
Changes in additional coagulation and clinical chemistry analysis pa-
rameters are shown in Supplementary Table 1. No inﬂuence of human
ﬁbrinogen concentrate on circulation, respiration or hematological pa-
rameters was observed (data not shown).
Single-dose toxicity
All doses of human ﬁbrinogen concentrate, whichwas administered
as a single intravenous dose, were well tolerated; all animals survived
until the scheduled end of the study and no adverse reactions wereFig. 1.Dose-dependent increases in (A)MCF and (B) A10 parameters of the FIBTEM test after cu
amplitude at 10 min; MCF, maximum clot ﬁrmness.recorded during the observation period. Body weight gain was physio-
logical and comparable with weight gain in the control animals
(Fig. 5). Macroscopic examination did not reveal any ﬁndings related
to the administration of human ﬁbrinogen concentrate (data not
shown).
Local tolerance
Clinical observations. Slight to moderate perivascular reddening was
detected 15 min after injection of human ﬁbrinogen concentrate
(intravenous and intra-arterial: n = 3 for treated animals, n = 2 for
control animals; and paravenous: n = 2 for treated animals, n = 1 for
control animals).
Histopathological ﬁndings. Slight to moderate hemorrhages were
observed in control (n = 1) and treated animals (n = 2) after intrave-
nous injection. No effects were detected after intra-arterial or
paravenous administration.
Neoantigenicity
In all three studies there was no indication for the formation of
neoepitopes induced by the implementation of a pasteurization step
during the manufacturing process of human ﬁbrinogen concentrate
(data not shown).
Discussion
The results of these non-clinical investigations demonstrate the safe-
ty of human ﬁbrinogen concentrate in different animal models. Admin-
istration of human ﬁbrinogen concentrate resulted in improved clot
strength, as measured by thromboelastometry, and was not associated
with any toxicological ﬁndings or the production of neoantigens follow-
ing the introduction of pasteurization in the manufacturing process.
Furthermore, no adverse reactionswere identiﬁed in the local tolerance
studies performed with human ﬁbrinogen concentrate.
Results of the pharmacodynamic study in rabbits support the efﬁca-
cyof humanﬁbrinogen concentrate in improving clot quality; its admin-
istration resulted in an increase in A5, A10 and MCF parameters of the
FIBTEM test. The ability of human ﬁbrinogen concentrate to restore
clot quality has been shown in a previous Phase II study in patients
with aﬁbrinogenemia. One hour after the infusion of human ﬁbrinogen
concentrate, MCF increased by a mean of 8.9 mm from baseline (0 mm;
p b 0.0001), indicative of hemostatic efﬁcacy (Manco-Johnson et al.,
2009). These results are also supported by in vitro studies (De Lorenzo
et al., 2006; Haas et al., 2008) and data from both retrospectivemulative dosing of 250 mg/kg humanﬁbrinogen concentrate in rabbits (Study 1). A10, clot
Variable Rabbit Rat
Cmax (mg/ml) 0.99 0.97
In vivo recovery (%) 79 65
AUC (h*mg/ml) 32 14
Clearance (ml/h/kg) 1.3 2.2
t1/2 (hours) 36 32
Fig. 2. Elimination curves and pharmacokinetic data of human ﬁbrinogen concentrate in rabbits and rats (Studies 2 and 3). AUC, area under the curve; Cmax, maximum concentration; t1/2,
terminal half-life.
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(Rahe-Meyer et al., 2009), including a randomized controlled trial inves-
tigating the use of ﬁbrinogen concentrate as hemostatic therapy in aor-
tic surgery (Rahe-Meyer et al., 2013b). Although few, and in a small
number of patients, a further ﬁve randomized controlled trials have
found evidence to support the efﬁcacy of human ﬁbrinogen concentrate,
compared with comparator or placebo, in patients undergoing major
surgery (Fenger-Eriksen et al., 2009b; Galas et al., 2014; Karlsson et al.,
2009; Lancé et al., 2012; Tanaka et al., 2014). There are also a number
of ongoing randomized controlled trials in a variety of clinical settings,
including cardiac surgery, trauma and postpartum hemorrhage.
The pharmacokinetic parameters of human ﬁbrinogen concentrate
in rabbits and rats appear generally comparable with a t1/2 of 36 h in
rabbits and 32 h in rats and a clearance of 1.3 ml/kg/h in rabbits and
2.2 ml/kg/h in rats. To our knowledge this is the ﬁrst study to determine
the pharmacokinetic parameters of human ﬁbrinogen concentrate in
animal models. By comparison, the pharmacokinetic characteristics ofFig. 3. Coagulation parameters of human ﬁbrinogen concentrate after successive dosing
thrombelastrography; WBCT, whole blood clotting time.human ﬁbrinogen concentrate have been assessed in patients with con-
genital ﬁbrinogen deﬁciency. The half-life of ﬁbrinogen is approximate-
ly 2-fold longer in humans than in animals, which is a typical
observation of human proteins in animals. In a Phase I trial in six pa-
tients with primary ﬁbrinogen deﬁciency the t1/2 of ﬁbrinogen was
found to be 2.7–3.6 days and the median in vivo recovery was
54.1–60.0% (Kreuz et al., 2005b). Similar results have been reported in
a Phase II trial in 15 patients with aﬁbrinogenemia (Manco-Johnson
et al., 2009). The t1/2 was found to be 2.3–4.9 days and the median in
vivo recovery was 52.5–97.43%. In addition, median clearance of the
product was 0.55 ml/h/kg and median AUC was 126.8 h∗mg/ml
(Manco-Johnson et al., 2009).
We found that human ﬁbrinogen concentrate increased ﬁbrinogen
levels in dogs after the ﬁnal dose was administered, which was
sustained over the remainder of the observation period of 60min, with-
out causing any toxic effects, indicating a good safety proﬁle of the prod-
uct. No inﬂuence of human ﬁbrinogen concentrate administration onin dogs (Study 4). MA, maximum amplitude; PTT, partial thromboplastin time; TEG,
Fig. 4. Changes in clinical-chemistry analysis parameters after successive dosing of human
ﬁbrinogen concentrate in dogs (Study 4).
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human ﬁbrinogen concentrate was conﬁrmed without any safety con-
cern in animals. Increases in ﬁbrinogen levels shortly after the adminis-
tration of human ﬁbrinogen concentrate have previously been shown in
patients undergoing aortic surgery (Solomon et al., 2013). This study
demonstrated that these increases in ﬁbrinogen are short-livedwithout
causing widespread hemostatic changes (Solomon et al., 2013). This
short-lived increase has also been shown in patients undergoing cardio-
pulmonary bypass (Karlsson et al., 2009) or radical cystectomy (Fenger-
Eriksen et al., 2009b) and in trauma patients (Schlimp et al., 2013).
Furthermore, 24 h post-operatively, ﬁbrinogen levels were comparable
between patients who did and did not receive ﬁbrinogen concentrate
(Fenger-Eriksen et al., 2009b; Karlsson et al., 2009), suggesting thatFig. 5. Change in body weight of mice and rats after a single intravenous dosthe effect of human ﬁbrinogen concentrate administration in the peri-
operative setting is unlikely to be observed beyond 24 h.
Acute toxicity studies showed that the administration of a single-
dose of human ﬁbrinogen concentrate was well tolerated with no ad-
verse reactions in mice up to 1000 mg/kg or in rats up to 300 mg/kg.
These doses provide an approximately 14-fold and 4-fold safety margin,
respectively, comparedwith the recommendeddose of humanﬁbrinogen
concentrate (RiaSTAP®) of 70 mg/kg body weight in patients with con-
genital ﬁbrinogen deﬁcit (RiaSTAP® PI, 2011). Following administration,
no relevant clinical or histopathological alteration in the injected area
was observed. Findings were considered to be due to the administration
procedure and not related to the product. In addition, human ﬁbrinogen
concentrate was shown to have good local tolerability after intravenous
administration — the intended route of delivery in humans.
Pasteurization reduces the risk of viral transmission and improves
the virus safety of plasma-derived human ﬁbrinogen concentrate. The
introduction of a pasteurization step into the production process of
plasma-derived human ﬁbrinogen concentrate did not yield any indica-
tion of newantigens or any alterations of the antigenic structures. A pre-
vious study using the same methodology as in our studies similarly
showed that no neoantigens could be detected in heat-treated plasma
protein preparations, including ﬁbrinogen concentrate and coagulation
factors VIII, IX, X and XIII (Ronneberger, 1986).
Furthermore, three recent systematic reviews have reported on
the safety of human ﬁbrinogen concentrate (Aubron et al., 2014;
Warmuth et al., 2012; Wikkelsø et al., 2013). In 2012, Warmuth et al.
identiﬁed three prospective controlled studies of massive hemorrhage
in the perioperative setting with a total of 53 participants (intervention
group, n=26; control group, n=27). Adverse events reported, includ-
ing myocardial infarction, pulmonary embolus and graft occlusion as
well as bleeding, major neurological events, atrial ﬁbrillation and renal
failure, occurred in 12% of patients receiving human ﬁbrinogen concen-
trate compared with 44% of patients in the control group (Warmuth
et al., 2012). In 2014, Aubron et al. identiﬁed twelve studies in trauma
patients, including four case reports and eight observational studies.
None of the studies reported a signiﬁcant increase in adverse events
with the administration of human ﬁbrinogen concentrate in this popu-
lation (Aubron et al., 2014). A Cochrane review of human ﬁbrinogen
concentrate use in bleeding patients published in 2013 identiﬁed six
randomized controlled trials with a total of 248 participants. No adverse
events, including thrombotic episodes, caused by treatment with
human ﬁbrinogen concentrate could be identiﬁed (Wikkelsø et al.,
2013). A study in cardiovascular surgery showed a signiﬁcant decrease
in the incidence of thrombotic/thromboembolic events (3.19% to
1.77%; p= 0.0115) with the implementation of a thromboelastometry
(ROTEM)-guided coagulation management algorithm incorporating
human ﬁbrinogen concentrate as ﬁrst-line hemostatic therapy
(Görlinger et al., 2011). In addition, the product was not associated
with an increased risk of thrombotic events in an animal model of ve-
nous stasis (Dickneite et al., 2009). Overall, these ﬁndings suggest ae of isotonic saline or human ﬁbrinogen concentrate (Studies 5 and 6).
76 A. Beyerle et al. / Toxicology and Applied Pharmacology 280 (2014) 70–77low thrombogenic potential for ﬁbrinogen concentrate. This has been
borne out by a 22-year pharmacosurveillance programof human ﬁbrin-
ogen concentrate (Haemocomplettan® P), which reported an incidence
rate of 1.59–6.61 events per 105 treatment episodes (Dickneite et al.,
2009).
The main limitation of the studies described in this report is that
they were carried out in animals and any extrapolation of the results
to humans should be made with caution. However, it must be noted
that non-clinical studies in animals are a necessity and the model spe-
cies used have demonstrated great utility for the types of studies per-
formed. The studies were also carried out in healthy non-bleeding
animals. Therefore, the impact of human ﬁbrinogen concentrate on
the parameters studied may be different than would be seen in a hem-
orrhagic model. The results of our non-clinical experiments are being
published in light ofmore recent data obtained fromprospective clinical
studies and appear to support these clinical ﬁndings.
Conclusion
In this series of non-clinical studies, human ﬁbrinogen concentrate
was shown to be pharmacodynamically active and well tolerated, with
no adverse events and no inﬂuence on circulation, respiration or hema-
tological parameters, and overall demonstrating a good safety proﬁle.
This data adds to the safety information available to date, strengthening
the current body of knowledge on this hemostatic agent for clinicians
and the scientiﬁc community.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.taap.2014.07.019.
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